Department of Medicine, Division of Rheumatology, Hub for Collaborative Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Rheumatology, 6th Floor, Milwaukee, WI 53226, USA.
Department of Medicine, Division of Rheumatology, Hub for Collaborative Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Rheumatology, 6th Floor, Milwaukee, WI 53226, USA.
Rheum Dis Clin North Am. 2023 Aug;49(3):505-521. doi: 10.1016/j.rdc.2023.03.005. Epub 2023 Apr 18.
Prolonged glucocorticoid tapers have been the standard of care for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), but recent advancements have improved outcomes for patients with GCA while reducing glucocorticoid-related toxicities. Many patients with GCA and PMR still experience persistent or relapsing disease, and cumulative exposure to glucocorticoids for both diseases remains high. The objective of this review is to define current treatment approaches as well as new therapeutic targets and strategies. Studies investigating inhibition of cytokine pathways, including interleukin-6, interleukin-17, interleukin-23, granulocyte-macrophage colony-stimulating factor, Janus kinase-signal transduction and activator of transcription, and others, will be reviewed.
糖皮质激素逐渐减量一直是巨细胞动脉炎（GCA）和风湿性多肌痛（PMR）的标准治疗方法，但最近的进展改善了 GCA 患者的预后，同时减少了糖皮质激素相关的毒性。许多 GCA 和 PMR 患者仍存在持续性或复发性疾病，两种疾病的糖皮质激素累积暴露量仍然很高。本综述的目的是定义当前的治疗方法以及新的治疗靶点和策略。研究中包括抑制细胞因子途径，如白细胞介素-6、白细胞介素-17、白细胞介素-23、粒细胞-巨噬细胞集落刺激因子、Janus 激酶-信号转导和转录激活因子等，这些研究将进行综述。
